The myasthenia gravis treatment market is anticipated to grow at a CAGR of 7.14% from US$1.973 billion in 2025 to US$2.785 ...

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile in adult patients with generalized myasthenia gravis, offering a promising ...

As a result, the muscles become weak when a person performs repeated physical movements. The disease is neither contagious nor inherited but it is often misunderstood as a psychological issue or ...

Myasthenia gravis is a serious ... leaving patients prone to infections and other side effects. Antibodies like Ocrevus also struggle to penetrate the CNS and hit MS at the site of the problem.

The US Food and Drug Administration (FDA) has approved a pre-filled syringe version of argenx’s Vyvgart, giving generalised ...

Rystiggo is the first therapy for both subtypes of the rare disease, caused by pathological auto-antibodies that ... and chief executive of the Myasthenia Gravis Foundation of America.

Hansa Biopharma AB, "Hansa" or the "Company" , today announced its interim report for January-March 2025. Peter Nicklin, Chairman of the Board, Hansa Biopharma said, "In Q1, the Company delivered ...

In addition, difficult-to-treat rheumatoid arthritis and myasthenia gravis readouts are also scheduled for 2027. Immunovant is aiming to report potentially registrational data in Sjögren’s ...

关于全身型重症肌无力 全身型重症肌无力（generalized myasthenia gravis, gMG）是一种罕见的自身免疫性疾病，主要表现为肌肉功能丧失、骨骼肌波动性无 ...